The role radiotherapy in non-small-cell lung cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Senan, S ^a   Lagerwaard, F J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; GEMCITABINE; MITOMYCIN C; PACLITAXEL; VINBLASTINE; VINDESINE;

ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGITIS; HIGH RISK PATIENT; HUMAN; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; PANCOAST TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION PNEUMONIA; STEREOTAXIC SURGERY; THORAX CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS;

EID: 21344442435     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi726     Document Type: Article

References (49)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
2. Janssen-Heijnen ML, Schipper MR, Razenberg PP et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21: 105-113.
3. Flehinger BJ, Melamed MR. Current status of screening for lung cancer. Chest Surg Clin N Am 1994; 4: 1-15.
4. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation- only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2002; 121: 1155-1158.
5. Qiao X, Tullgren O, Lax I et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003; 41: 1-11.
6. Uematsu M, Shioda A, Suda A et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001; 51: 666-670.
7. Timmerman R, Papiez L, McGarry R et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003; 124: 1946-1955.
8. Onishi H, Araki T, Shirato H et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101: 1623-1631.
9. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000; 46: 516-517.
10. Curran WJ, Scott CB, Langer CJ et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22: 621 (Abstr 2499).
11. Albain KS, Scott CB, Rusch VR et al. Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): First outcome analysis of North American Intergroup trial 0139 (RTOG 93-09). Lung Cancer 2003; 41 (Suppl 2): S4.
12. Van Schil PE, Van Meerbeeck JP, Kramer G et al. Surgery after induction chemotherapy: Morbidity and mortality in the first 100 patients of the surgery arm of EORTC 08941 trial. Lung Cancer 2003; 41 (Suppl 2): S45.
13. Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a sub-classification and implications. J Clin Oncol 2000; 18: 2981-2989.
14. Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-1892.
15. Sause W, Kolesar P, Taylor SIV et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 358-364.
16. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
17. Fournel P, Perol M, Gilles R et al. A randomized phase III trial of sequential versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 2001; 20: 312a (Abstr 1246).
18. Rowell N, O'Rourke N. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004; 4: CD002140.
19. Saunders M, Dische S, Barrett A et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999; 52: 137-148.
20. Belani CP, Wang W, Johnson DH et al. Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and B non-small-cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Proc Am Soc Clin Oncol 2003; 22: 622 (Abstr 2500).
21. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
22. Rusch VW, Giroux DJ, Kraut MJ et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121: 472-483.
23. Tsuboi M, Kunitoh H, Kato H et al. A phase II trial of pre-operative chemoradiotherapy followed by surgery in Pancoast tumors: initial report of Japan Clinical Oncology Group trial (JCOG 9806). Lung Cancer 2003; 41 (Suppl 2): S78.
24. Senan S, DeRuysscher D, Giraud P et al. Literature-based recommendations for treatment planning and execution for high-precision radiotherapy in lung cancer. Radiother Oncol 2004; 71: 139-146.
25. Bradley J, Graham MV, Winter K et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 318-328.
26. Senan S, Chapet O, Lagerwaard FJ, Ten Haken RK. Defining target volumes for non-small cell lung carcinoma. Semin Radiat Oncol 2004; 14: 308-314.
27. Gould MK, Kuschner WG, Rydzak CE et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139: 879-892.
28. El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 2003; 89: 2184-2189.
29. Bradley JD, Ieumwananonthachai N, Purdy JA et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002; 52: 49-57.
30. Marks LB, Garst J, Socinski MA et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 2004; 22: 4329-4340.
31. Miller KL, Shafman TD, Anscher MS et al. Bronchial stenosis: An underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys 2005; 61: 64-69.
32. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352: 257-263.
33. 18F-FDG PET et al. provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42: 1596-1604.
34. Bradley J, Thorstad WL, Mutic S et al. Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59: 78-86.
35. Annema JT, Hoekstra OS, Smit EF et al. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. Lung Cancer 2004; 44: 53-60.
36. Keall P. 4-dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol 2004; 14: 81-90.
37. Underberg RWM, Lagerwaard FJ, Cuijpers JP et al. Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys 2004; 60: 1283-1290.
38. Underberg RWM, Lagerwaard FJ, Slotman BJ et al. Benefits of respiration-gated stereotactic radiotherapy for stage I lung cancer-An analysis of 4DCT datasets. Int J Radiat Oncol Biol Phys 2005; In press.
39. Grills IS, Yan D, Martinez AA et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003; 57: 875-890.
40. Bleehan NM, Girling DJ, Machin D et al. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992; 65: 934-941.
41. Macbeth FR, Bolger JJ, Hopwood P et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 1996; 8: 167-175.
42. Kramer GWPM, Wanders SL, Noordijk EM et al. Randomized Dutch National study of the effect of irradiation with different treatment schemes in the palliation of Non-Small-Cell Lung-Cancer (NSCLC). Lung Cancer 2003; 41 (Suppl 2): S38.
43. Bezjak A, Dixon P, Brundage M et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC. 15). Int J Radiat Oncol Biol Phys 2002; 54: 719-728.
44. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 2000; 83: 447-453.
45. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-1080.
46. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-751.
47. Lagerwaard FJ, Levendag PC, Nowak PJ et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43: 795-803.
48. Noordijk EM, Vecht CJ, Haaxma-Reiche H et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994; 29: 711-717.
49. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672.